ArticleCardiovascular diabetology2026
Circulating amino acids and Type 2 diabetes in a Latin American population-based cohort.
Article in Cardiovascular diabetology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
BACKGROUND AND
aimsMetabolomics enables the identification of circulating biomarkers for Type 2 diabetes (T2D). Most studies of circulating amino acids and T2D are from European and Asian, few from Latin America. We aimed to evaluate plasma amino acids and risk of T2D in an agricultural population from Molina County, Central Chile.
methodsMAUCO is a population-based prospective cohort of 9462 participants aged 38 to 74 years at enrollment in 2014. From 2000 participants (47% women) selected for metabolomic analysis 1738 had enough serum sample for this study. We quantified circulating branched-chain amino acids (BCAAs), as well as phenylalanine, tyrosine, alanine, glutamine, glycine, and histidine using nuclear magnetic resonance, while T2D was diagnosed according to the American Diabetes Association guidelines at enrollment and follow-up. We analyzed the association of the circulating amino acids on T2D prevalence and incidence, using multiple logistic and Cox regression models adjusted by sex, age, education, body mass index, smoking, alcohol consumption, physical activity, and Mediterranean diet score.
resultsIn the cross-sectional analysis, plasma BCAAs (aOR 2.1; 95% CI 1.80-2.50), and plasma alanine (aOR 1.57; 95% CI 1.37-1.80) were associated with T2D, while histidine, glycine, and glutamine were inversely associated with T2D risk (aOR 0.80; 95% CI 0.69-0.91; 0.68; 95% CI 0.57-0.80, and 0.64; 95% CI 0.56-0.74, respectively). After a median follow-up of 4.3 years, we diagnosed 127 (10.5% incidence) new T2D cases. Prevalence and incidence analysis yielded a similar pattern, but only high isoleucine reached statistical significance in the incidence of T2D (aHR 1.31; 95% CI 1.10-1.56).
conclusionElevated plasma BCAA concentrations in Chilean adults were significantly associated with the prevalence of T2D, while only high isoleucine was associated with the incidence of T2D. These findings could inform risk stratification by specific metabolic mechanisms and guide future research on targeted interventions.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.